Vitiligo - 白斑
指の白斑は、他の部位よりも治療が困難です。白斑症は美容的に見たくない他にすべて正常で、伝染しません。皮膚科では、光線治療またはレーザー治療（excimer）を週に2〜3回ずつ少なくとも1年以上治療するのが最も効果的な治療法です。財政的な理由や忙しくて病院に頻繁に行けない場合は、家庭用に許可された光線治療器を試してみることができます。
まぶたの白斑
手持ちの白斑
relevance score : -100.0%
References白斑は、メラノサイトの喪失により白い皮膚の斑点が生じる一般的な皮膚疾患です。最近の研究では、自己免疫疾患であることが示されています。見た目の問題として認識されることが多いですが、精神的な健康や日常生活に深く影響を与える可能性があります。2011年に、専門家は「segmental vitiligo」と呼ばれるタイプを他のタイプとは別に分類しました。
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
活動性白斑の患者には、全身性糖質コルチコイド、光線療法、全身性免疫抑制剤など、いくつかの治療選択肢があります。安定期の白斑患者には、局所コルチコステロイド、局所カルシニューリン阻害剤、光線療法、そして移植処置により症状が軽減されることがあります。白斑の根本的な病態解明の最近の進展は、標的療法の開発につながっています。現在、JAK阻害剤が最も有望とされており、他の免疫抑制剤に共通する感染症リスクや全身性副作用があるにもかかわらず、良好な忍容性と機能的な改善が期待できます。現在進行中の研究では、白斑の発症に関与する重要なサイトカイン（IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF）を特定することが目指されています。これらのサイトカインを阻害することは、動物モデルや一部の患者で有望であることが示されています。さらに、miRNA-based therapeutics や adoptive Treg cell therapy に関する研究も進められています。
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
根治的な治療法は確立されていません。肌の色が薄い人には、通常、日焼け止めとメイクのみが推奨されます。他の治療オプションとしては、ステロイドクリームや光線療法が検討されることがあります。
○ 処理
#Phototherapy
#Excimer laser
#Tacrolimus ointment